
Danish medtech firm Coloplast has released figures for the second quarter of fiscal 2021/2022, as well as a downgrade to the firm’s organic growth guidance.
According to Thursday’s report, Coloplast is now expecting 6–7% organic growth for the full year, which is an adjustment from the previously reported 7%.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app